Pyridostigmine ( DrugBank: Pyridostigmine )
4 diseases
| ID | Disease name (Link within this page) | Number of trials |
|---|---|---|
| 3 | Spinal muscular atrophy | 3 |
| 6 | Parkinson disease | 3 |
| 11 | Myasthenia gravis | 8 |
| 256 | Muscle glycogenosis | 1 |
3. Spinal muscular atrophy
Clinical trials : 237 / Drugs : 123 - (DrugBank : 29) / Drug target genes : 51 - Drug target pathways : 75
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT02941328 (ClinicalTrials.gov) | December 2015 | 30/9/2016 | SPACE Trial: Pyridostigmine vs Placebo in SMA Types 2, 3 and 4 | A Phase II, Mono-center, Placebo-controlled, Double-blind, Crossover Trial to Investigate Effect and Efficacy of Pyridostigmine in Dutch Patients With Spinal Muscular Atrophy Types 2, 3 and 4 | Spinal Muscular Atrophy;SMA;Kugelberg-Welander Disease | Drug: Pyridostigmine;Drug: Placebo | UMC Utrecht | NULL | Completed | 12 Years | N/A | All | 39 | Phase 2 | Netherlands |
| 2 | EUCTR2011-004369-34-NL (EUCTR) | 22/04/2015 | 03/11/2014 | SPACE trial SMA and Pyridostigmine in Adults and Children; Experimental trial to assess effect of pyridostigmine compared to placebo in patients with spinal muscular atrophy types 2, 3 and 4 | SPACE trial SMA and Pyridostigmine in Adults and Children; Efficacy trial Phase II, mono-center, doubleblind, placebo-controlled, crossover trial to assess efficacy of pyridostigmine in patients with spinal muscular atrophy types 2, 3 and 4 - SPACE trial | Proximal spinal muscular atrophy (SMA) is characterized by weakness of predominantly axial and proximal muscle groups and is caused by homozygous deletion of the survival motor neuron 1 (SMN1)-gene. There are 4 SMA types (type 1-4), with a descending order of severity. Age at onset and achieved motor milestones are the characteristics to define severity. Treatment of SMA is exclusively supportive. MedDRA version: 17.1;Level: LLT;Classification code 10068209;Term: Spinal muscular atrophy adult onset;System Organ Class: 100000004850 MedDRA version: 17.1;Classification code 10051203;Term: Spinal muscular atrophy congenital;System Organ Class: 100000004850 ;Therapeutic area: Diseases [C] - Nervous System Diseases [C10] | Trade Name: pyridostigmine bromide Product Name: Mestinon Product Code: RVG 03820 | Universtiy Medical Center Utrecht | NULL | Not Recruiting | Female: yes Male: yes | 45 | Human pharmacology (Phase 1): no Therapeutic exploratory (Phase 2): yes Therapeutic confirmatory - (Phase 3): no Therapeutic use (Phase 4): no | Netherlands | ||
| 3 | NCT02227823 (ClinicalTrials.gov) | July 2014 | 20/8/2014 | Safety and Efficacy Study of Pyridostigmine on Patients With Spinal Muscular Atrophy Type 3 | Safety and Efficacy Study of Anti-cholinesterase Therapy on the Motor Functions in Patients With Spinal Muscular Atrophy Type 3. | Spinal Muscular Atrophy Type 3 | Drug: Pyridostigmine Bromide | Centre Hospitalier Régional de la Citadelle | NULL | Recruiting | 6 Years | N/A | Both | 20 | Phase 2 | Belgium |
6. Parkinson disease
Clinical trials : 2,307 / Drugs : 2,007 - (DrugBank : 349) / Drug target genes : 188 - Drug target pathways : 199
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT05603715 (ClinicalTrials.gov) | August 10, 2022 | 12/9/2022 | Pyridostigmine for the Treatment of Constipation in Parkinson Disease | Pyridostigmine for the Treatment of Constipation in Parkinson Disease | Parkinson Disease;Constipation | Drug: Pyridostigmine Bromide | University of Vermont Medical Center | NULL | Recruiting | 18 Years | N/A | All | 16 | Phase 2 | United States |
| 2 | EUCTR2012-000122-21-DK (EUCTR) | 10/08/2012 | 07/06/2012 | Improving the blood pressure regulating system in patients with parkinsons disease | Acethylcholineesterase inhibition and orthostatic hypotension in patients with parkinsons disease | Ortostatic hypotension in patients with Parkinsons disease MedDRA version: 14.1;Level: PT;Classification code 10031127;Term: Orthostatic hypotension;System Organ Class: 10047065 - Vascular disorders;Therapeutic area: Body processes [G] - Circulatory and Respiratory Physiological Phenomena [G09] | Trade Name: Mestinon Product Name: Mestinon INN or Proposed INN: PYRIDOSTIGMINE BROMIDE Other descriptive name: Mestinon | Department of Neurology, Roskilde Hospital | NULL | Not Recruiting | Female: yes Male: yes | 20 | Phase 2 | Denmark | ||
| 3 | NCT01993680 (ClinicalTrials.gov) | June 2012 | 27/4/2012 | Orthostatic Dysregulation and Associated Gastrointestinal Dysfunction in Parkinson's Disease -Treatment | A Monocentric Randomized, Controlled, Double Blind, Crossover Phase II Trial to Show Non-inferiority of the Effect of Pyridostigmine Bromide vs. Fludrocortisone on Symptoms of Autonomic Dysregulation in Parkinson's Disease | Autonomic Disturbances in Parkinson's Disease | Drug: Pyridostigmine bromide;Drug: fludrocortisone | Christian Baumann | NULL | Completed | 50 Years | 80 Years | All | 18 | Phase 2 | Switzerland |
11. Myasthenia gravis
Clinical trials : 332 / Drugs : 234 - (DrugBank : 81) / Drug target genes : 45 - Drug target pathways : 127
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | ITMCTR2200005637 | 2022-01-01 | 2021-06-20 | Efficacy of Buzhong Yiqi Decoction in the Treatment of Ocular Myopathy Myasthenia Gravis (MG) Patients with Spleen and Kidney Deficiency Type: a Randomized Controlled Trial | Efficacy of Buzhong Yiqi Decoction in the Treatment of Ocular Myopathy Myasthenia Gravis (MG) Patients with Spleen and Kidney Deficiency Type: a Randomized Controlled Trial | Ocular myasthenia gravis | contrast group:Pyridostigmine Bromide Tablets;Experimental group:Buzhong Yiqi Decoction; | Affiliated Jiangmen Traditional Chinese Medicine Hospital of Ji'nan University | NULL | Recruiting | 18 | 80 | Both | contrast group:27;Experimental group:27; | China | |
| 2 | ChiCTR2100047506 | 2022-01-01 | 2021-06-20 | Efficacy of Buzhong Yiqi Decoction in the Treatment of Ocular Myopathy Myasthenia Gravis (MG) Patients with Spleen and Kidney Deficiency Type: a Randomized Controlled Trial | Efficacy of Buzhong Yiqi Decoction in the Treatment of Ocular Myopathy Myasthenia Gravis (MG) Patients with Spleen and Kidney Deficiency Type: a Randomized Controlled Trial | Ocular myasthenia gravis | Experimental group:Buzhong Yiqi Decoction;contrast group:Pyridostigmine Bromide Tablets; | Affiliated Jiangmen Traditional Chinese Medicine Hospital of Ji’nan University | NULL | Recruiting | 18 | 80 | Both | Experimental group:27;contrast group:27; | China | |
| 3 | NCT04226170 (ClinicalTrials.gov) | April 8, 2021 | 9/1/2020 | Study of Pyridostigmine With Ondansetron in Subjects With Anti-AchR Positive Myasthenia Gravis | A Phase II, Study to Evaluate the Safety and Tolerability of Pyridostigmine When Given With Ondansetron to Subjects With Anti-AchR Positive Myasthenia Gravis | Myasthenia Gravis | Drug: DAS-001 | DAS-MG, Inc | NULL | Recruiting | 18 Years | N/A | All | 24 | Phase 2 | United States |
| 4 | NCT04768465 (ClinicalTrials.gov) | January 1, 2021 | 21/2/2021 | Tacrolimus Combined With Low-dose Prednisone for Treatment of Myasthenia Gravis | Effectiveness and Safety of Tacrolimus Combined With Low-dose Prednisone for Treatment of Myasthenia Gravis: A Real-world Study | Myasthenia Gravis | Drug: Pyridostigmine, Prednisone, Tacrolimus;Drug: Pyridostigmine, Tacrolimus | Da, Yuwei, M.D. | NULL | Recruiting | 18 Years | N/A | All | 160 | China | |
| 5 | NCT03510546 (ClinicalTrials.gov) | April 9, 2018 | 6/4/2018 | Effect of Pyridostigmine (Mestinon) on Muscle Strength in Myasthenia Gravis | Effect of Pyridostigmine (Mestinon) on Muscle Strength in Myasthenia Gravis | Myasthenia Gravis | Drug: Pyridostigmine;Drug: Placebo oral capsule | University of Aarhus | Aarhus University Hospital | Recruiting | 18 Years | 90 Years | All | 44 | Phase 4 | Denmark |
| 6 | EUCTR2017-002599-15-DK (EUCTR) | 07/11/2017 | 07/07/2017 | Effect of pyridostigmine (Mestinon®) on muscle strength in Myasthenia Gravis. | Effect of pyridostigmine (Mestinon®) on muscle strength in Myasthenia Gravis. | Myasthenia Gravis MedDRA version: 20.0;Level: HLT;Classification code 10071942;Term: Myasthenia gravis and related conditions;System Organ Class: 100000004859;Therapeutic area: Diseases [C] - Musculoskeletal Diseases [C05] | Trade Name: Mestinon INN or Proposed INN: pyridostigmine Other descriptive name: PYRIDOSTIGMINE | Aarhus University | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | 32 | Phase 4 | Denmark | ||
| 7 | ChiCTR-OCC-13003090 | 2012-12-20 | 2013-03-02 | Research on micrornas expression of Myasthenia gravis and the relationship with TH1, TH2 cells secrete cytokines | Research on micrornas expression of Myasthenia gravis and the relationship with TH1, TH2 cells secrete cytokines | Myasthenia gravis | experimental group:Pyridostigmine Bromide;control group:nothing; | The first affiliated hospital of Guangzhou university of Traditional Chinese medicine | NULL | Completed | 18 | 65 | Both | experimental group:30;control group:30; | China | |
| 8 | ChiCTR-TRC-13004125 | 2010-10-01 | 2013-06-08 | The study on the pathogenesis of spleen-kidney deficiency type myasthenia gravis and the interference effect of Jianji Ning Granule on the patients | The study on the pathogenesis of spleen-kidney deficiency type myasthenia gravis and the interference effect of Jianji Ning Granule on the patients | Myasthenia gravis | trial:Jianji Ning Granule combined with olfactory pyridostigmine tablets ;Control:olfactory pyridostigmine tablets ; | Longhua Hospital Affiliated to Shanghai University of traditional Chinese Medicine | NULL | Completed | 14 | 75 | Both | trial:30;Control:30; | I+2 (Phase 1+Phase 2) | China |
256. Muscle glycogenosis
Clinical trials : 180 / Drugs : 133 - (DrugBank : 29) / Drug target genes : 25 - Drug target pathways : 105
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT02357225 (ClinicalTrials.gov) | August 2015 | 23/1/2015 | A Pilot Study of Pyridostigmine in Pompe Disease | Evaluation of Respiratory and Skeletal Muscle Functions in Response to Acetylcholinesterase Inhibitors in Pompe Disease | Pompe Disease | Drug: Pyridostigmine Bromide | University of Florida | NULL | Terminated | 8 Years | 60 Years | All | 2 | Early Phase 1 | United States |